Evidence map›Paper›PMID 30112846›Full record

ArticleStem cells translational medicine2018

Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial.

Eun Hye Park, Hee-Suk Lim, Seunghee Lee, Kyounghwan Roh, Kwang-Won Seo, Kyung-Sun Kang, Kichul Shin

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07546942 (Autism Spectral Disorder), which is not on this map. Cited by 85 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07546942 phase1 / phase2enrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Autism Spectral Disorder (ASD) In Adolescent-Adults Treated by Multimodal Protocol: IV Autologous cSVF, Interval IV Autologous MSCs (Cryopreserved), Strick Ketogenic Diet RESET Program, and Fecal Microbiota Transplantation (FMT)

TypeinterventionalSponsorBlack Tie Medical, Inc.Ran2026 to 2030Enrolled50ConditionsAutism Spectrum Disorder, Autism, Autism Spectral DisorderArmsAutologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol, Trial combines use of cSVF and MSCs (cryopres) with diet modification and FMT (fecal material Transplant in adult ASD patients, FMT (Fecal Material Tranplantation)
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. PRRX1 upregulates PD-L1 in human mesenchymal stem cells.In vitro cellular & developmental biology. Animal · 2024
    Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eun Hye ParkDivision of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Hee-Suk LimDivision of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.
Seunghee LeeInstitute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, South Korea.
Kyounghwan RohInstitute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, South Korea.
Kwang-Won SeoInstitute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, South Korea.
Kyung-Sun KangInstitute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, South Korea.
Kichul ShinDivision of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.ORCID 0000-0002-6749-7598

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on immunomodulatory actions of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs), in vitro or preclinical studies of hUCB-MSCs have been conducted extensively in rheumatoid arthritis (RA). However, few human trials have investigated the outcomes of hUCB-MSC infusions. The CURE-iv trial was a phase I, uncontrolled, open label trial for RA patients with moderate disease activity despite treatment with methotrexate. The patients received a single intravenous infusion of 2.5 × 10

Indexed as

Mesenchymal Stem Cell TransplantationAgedArthritis, RheumatoidBlood SedimentationC-Reactive ProteinCytokinesFemaleFetal BloodHealth StatusHumansInfusions, IntravenousMaleMesenchymal Stem CellsMethotrexateMiddle AgedSeverity of Illness IndexC-Reactive ProteinCytokinesMethotrexateClinical trialMesenchymal stem cellRheumatoid arthritisSafetyUmbilical cord blood

Identifiers

PMID30112846
PMCPMC6127229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.